EA200100867A1 - Сульфаматогидроксамовая кислота как ингибитор металлопротеаз - Google Patents
Сульфаматогидроксамовая кислота как ингибитор металлопротеазInfo
- Publication number
- EA200100867A1 EA200100867A1 EA200100867A EA200100867A EA200100867A1 EA 200100867 A1 EA200100867 A1 EA 200100867A1 EA 200100867 A EA200100867 A EA 200100867A EA 200100867 A EA200100867 A EA 200100867A EA 200100867 A1 EA200100867 A1 EA 200100867A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- acid
- sulfamatogidroxamic
- metalloproteas
- inhibitor
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Раскрыты соединения сульфаматогидроксамовой кислоты, которые, inter alia, угнетают активность матричных металлопротеаз, а также способ получения упомянутых соединений и промежуточных соединений, используемых при синтезировании упомянутых соединений, а также способ лечения, который включает введение хозяину, имеющему состояние, связанное с патологической активностью матричной металлопротеазы, предусматриваемого соединения сульфаматогидроксамовой кислоты в количестве, эффективном для подавления матричной металлопротеазы.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11918199P | 1999-02-08 | 1999-02-08 | |
PCT/US2000/003061 WO2000046221A1 (en) | 1999-02-08 | 2000-02-07 | Sulfamato hydroxamic acid metalloprotease inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200100867A1 true EA200100867A1 (ru) | 2002-04-25 |
EA005500B1 EA005500B1 (ru) | 2005-02-24 |
Family
ID=22382974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200100867A EA005500B1 (ru) | 1999-02-08 | 2000-02-07 | Сульфаматогидроксамовая кислота как ингибитор металлопротеаз |
Country Status (27)
Country | Link |
---|---|
US (3) | US6448250B1 (ru) |
EP (1) | EP1157021A1 (ru) |
JP (1) | JP2002536373A (ru) |
KR (1) | KR20010102000A (ru) |
CN (1) | CN1216056C (ru) |
AP (1) | AP2001002240A0 (ru) |
AR (1) | AR036585A1 (ru) |
AU (1) | AU775701B2 (ru) |
BG (1) | BG105788A (ru) |
BR (1) | BR0008440A (ru) |
CA (1) | CA2362230A1 (ru) |
CZ (1) | CZ20012849A3 (ru) |
EA (1) | EA005500B1 (ru) |
EE (1) | EE200100410A (ru) |
GE (1) | GEP20043238B (ru) |
HK (1) | HK1049660B (ru) |
HR (1) | HRP20010660A2 (ru) |
HU (1) | HUP0200119A3 (ru) |
IL (1) | IL144783A0 (ru) |
IS (1) | IS6039A (ru) |
MX (1) | MXPA01007987A (ru) |
NO (1) | NO20013850L (ru) |
PL (1) | PL350193A1 (ru) |
SK (1) | SK11352001A3 (ru) |
WO (1) | WO2000046221A1 (ru) |
YU (1) | YU57101A (ru) |
ZA (1) | ZA200106492B (ru) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6747027B1 (en) | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
US6794511B2 (en) | 1997-03-04 | 2004-09-21 | G. D. Searle | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US6696449B2 (en) | 1997-03-04 | 2004-02-24 | Pharmacia Corporation | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
US20010039287A1 (en) * | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
NZ503485A (en) | 1997-11-14 | 2002-10-25 | G | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6750228B1 (en) | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
US6511993B1 (en) | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
US6683093B2 (en) | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
IL158454A0 (en) | 2001-05-11 | 2004-05-12 | Pharmacia Corp | Aromatic sulfone hydroxamates and their use as protease inhibitors |
US6683078B2 (en) | 2001-07-19 | 2004-01-27 | Pharmacia Corporation | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
GB0119396D0 (en) * | 2001-08-09 | 2001-10-03 | Celltech R&D Ltd | Hydroxamic acid derivatives |
GB0119474D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
ATE399012T1 (de) | 2002-04-03 | 2008-07-15 | Topotarget Uk Ltd | Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren |
US20050209278A1 (en) * | 2002-04-25 | 2005-09-22 | Mcdonald Joseph J | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
WO2003091247A2 (en) * | 2002-04-25 | 2003-11-06 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
JP2006502980A (ja) * | 2002-06-25 | 2006-01-26 | ファルマシア・コーポレーション | アリールスルホニルヒドロキサム酸およびアミド誘導体、ならびにプロテアーゼ阻害薬としてのそれらの使用 |
GB0216382D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
AU2003300800A1 (en) * | 2002-11-25 | 2004-06-18 | Pharmacia Corporation | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors |
JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
WO2004065354A1 (en) | 2003-01-17 | 2004-08-05 | Topotarget Uk Limited | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors |
US20050043533A1 (en) * | 2003-03-25 | 2005-02-24 | Babiak Kevin A. | Process for making alpha-substituted hydroxamic acids |
GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
EP1743638A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Pharmaceutical formulations of substituted pyrazoline compounds |
CA2634701C (en) * | 2005-12-21 | 2014-07-29 | Decode Genetics Ehf | Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation |
AU2007334519A1 (en) * | 2006-12-14 | 2008-06-26 | Merck Sharp & Dohme Corp. | Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment |
CN101687658B (zh) | 2007-05-14 | 2013-07-24 | 因温斯特技术公司 | 高效反应器和方法 |
WO2013039851A1 (en) | 2011-09-12 | 2013-03-21 | Mallinckrodt Llc | Optical agents for imaging and visualization of matrix metalloproteinase enzymes |
WO2018037254A1 (en) * | 2016-08-24 | 2018-03-01 | Tfchem | Difluorinated compounds as depigmenting or lightening agents |
US11590226B2 (en) | 2018-06-29 | 2023-02-28 | Loyola University Of Chicago | Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1067965A (en) | 1912-10-31 | 1913-07-22 | C T Ham Mfg Company | Vehicle-lamp. |
GB1067965A (en) * | 1965-01-22 | 1967-05-10 | Beecham Group Ltd | Penicillins, esters, amides and salts thereof |
US4595700A (en) | 1984-12-21 | 1986-06-17 | G. D. Searle & Co. | Thiol based collagenase inhibitors |
US4882434A (en) | 1986-10-29 | 1989-11-21 | Takeda Chemical Industries, Ltd. | Gamma-lactonecarboxylic acid derivatives and their use as antibacterial agents or intermediates |
DE3811777A1 (de) * | 1988-04-08 | 1989-10-19 | Hoechst Ag | Heterocyclisch substituierte alkyl- und alkenylsulfonylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als herbizide oder pflanzenwachstumsregulatoren |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
JP3122161B2 (ja) | 1991-05-16 | 2001-01-09 | 武田薬品工業株式会社 | γ−ラクトン免疫抑制剤 |
ATE150452T1 (de) | 1992-04-07 | 1997-04-15 | British Biotech Pharm | Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren |
US5376664A (en) | 1992-07-27 | 1994-12-27 | The Du Pont Merck Pharmaceutical Company | Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9307956D0 (en) | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
GB9320660D0 (en) | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
ATE191141T1 (de) | 1993-11-04 | 2000-04-15 | Liposome Co Inc | Behandlungsverfahren unter verwendung unilamellar-liposomaler arachiddonsäuremetabolit- formulierungen |
GB9323165D0 (en) | 1993-11-10 | 1994-01-05 | Chiros Ltd | Compounds |
GB9416897D0 (en) | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
CN1193978A (zh) | 1994-10-05 | 1998-09-23 | 奇罗斯恩有限公司 | 肽基化合物和它们作为金属蛋白酶抑制剂的医疗用途 |
HUP9902092A3 (en) | 1995-12-08 | 2000-12-28 | Agouron Pharmaceuticals Inc La | Metalloproteinase inhibitor benzenesulfonamide derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds |
DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
PT871439E (pt) | 1996-01-02 | 2004-08-31 | Aventis Pharma Inc | Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo) |
EP0912571B1 (en) * | 1996-06-20 | 2004-08-04 | Schering Corporation | Naphthyridines which affect il-4 and g-csf |
ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
PT970046E (pt) * | 1997-02-27 | 2004-04-30 | Wyeth Corp | N-hidroxi-2-(alquil, aril, ou heteroaril sulfanil, sulfinil ou sulfonil)-alquil, aril ou heteroaril amidas substituidas em 3 como inibidores de metaloproteinase de matriz |
WO1999024399A1 (en) | 1997-11-12 | 1999-05-20 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
NZ503485A (en) | 1997-11-14 | 2002-10-25 | G | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US20010039287A1 (en) | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
IL127496A0 (en) | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
EP1054858A1 (en) | 1998-02-19 | 2000-11-29 | American Cyanamid Company | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
AU2713500A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
-
2000
- 2000-02-07 EE EEP200100410A patent/EE200100410A/xx unknown
- 2000-02-07 KR KR1020017010040A patent/KR20010102000A/ko not_active Application Discontinuation
- 2000-02-07 EP EP00905996A patent/EP1157021A1/en not_active Withdrawn
- 2000-02-07 CZ CZ20012849A patent/CZ20012849A3/cs unknown
- 2000-02-07 US US09/499,276 patent/US6448250B1/en not_active Expired - Fee Related
- 2000-02-07 AP APAP/P/2001/002240A patent/AP2001002240A0/en unknown
- 2000-02-07 GE GEAP20006101A patent/GEP20043238B/en unknown
- 2000-02-07 CA CA002362230A patent/CA2362230A1/en not_active Abandoned
- 2000-02-07 PL PL00350193A patent/PL350193A1/xx not_active Application Discontinuation
- 2000-02-07 EA EA200100867A patent/EA005500B1/ru not_active IP Right Cessation
- 2000-02-07 SK SK1135-2001A patent/SK11352001A3/sk unknown
- 2000-02-07 BR BR0008440-9A patent/BR0008440A/pt not_active IP Right Cessation
- 2000-02-07 IL IL14478300A patent/IL144783A0/xx unknown
- 2000-02-07 AU AU27574/00A patent/AU775701B2/en not_active Ceased
- 2000-02-07 MX MXPA01007987A patent/MXPA01007987A/es unknown
- 2000-02-07 WO PCT/US2000/003061 patent/WO2000046221A1/en not_active Application Discontinuation
- 2000-02-07 CN CN008060339A patent/CN1216056C/zh not_active Expired - Fee Related
- 2000-02-07 HU HU0200119A patent/HUP0200119A3/hu active IP Right Revival
- 2000-02-07 YU YU57101A patent/YU57101A/sh unknown
- 2000-02-07 JP JP2000597291A patent/JP2002536373A/ja active Pending
- 2000-02-08 AR ARP000100538A patent/AR036585A1/es unknown
-
2001
- 2001-06-19 US US09/884,548 patent/US6372758B1/en not_active Expired - Fee Related
- 2001-08-07 BG BG105788A patent/BG105788A/bg unknown
- 2001-08-07 NO NO20013850A patent/NO20013850L/no not_active Application Discontinuation
- 2001-08-07 ZA ZA200106492A patent/ZA200106492B/en unknown
- 2001-08-07 IS IS6039A patent/IS6039A/is unknown
- 2001-09-07 HR HR20010660A patent/HRP20010660A2/hr not_active Application Discontinuation
-
2002
- 2002-02-26 US US10/084,713 patent/US6492367B1/en not_active Expired - Fee Related
-
2003
- 2003-02-07 HK HK03100924.8A patent/HK1049660B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SK11352001A3 (sk) | 2002-09-10 |
NO20013850L (no) | 2001-09-19 |
AP2001002240A0 (en) | 2001-09-30 |
WO2000046221A1 (en) | 2000-08-10 |
HUP0200119A3 (en) | 2003-04-28 |
JP2002536373A (ja) | 2002-10-29 |
US6448250B1 (en) | 2002-09-10 |
AU775701B2 (en) | 2004-08-12 |
EE200100410A (et) | 2002-12-16 |
EA005500B1 (ru) | 2005-02-24 |
KR20010102000A (ko) | 2001-11-15 |
BG105788A (bg) | 2002-02-28 |
HUP0200119A2 (en) | 2002-06-29 |
NO20013850D0 (no) | 2001-08-07 |
HK1049660A1 (en) | 2003-05-23 |
PL350193A1 (en) | 2002-11-18 |
AU2757400A (en) | 2000-08-25 |
EP1157021A1 (en) | 2001-11-28 |
IS6039A (is) | 2001-08-07 |
MXPA01007987A (es) | 2002-04-24 |
US6372758B1 (en) | 2002-04-16 |
ZA200106492B (en) | 2003-05-07 |
CZ20012849A3 (cs) | 2002-05-15 |
AR036585A1 (es) | 2004-09-22 |
YU57101A (sh) | 2005-06-10 |
CN1362954A (zh) | 2002-08-07 |
HK1049660B (zh) | 2006-05-12 |
IL144783A0 (en) | 2002-06-30 |
CN1216056C (zh) | 2005-08-24 |
GEP20043238B (en) | 2004-05-25 |
US6492367B1 (en) | 2002-12-10 |
HRP20010660A2 (en) | 2005-02-28 |
BR0008440A (pt) | 2002-03-26 |
CA2362230A1 (en) | 2000-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200100867A1 (ru) | Сульфаматогидроксамовая кислота как ингибитор металлопротеаз | |
ID18143A (id) | Penghambat metaloprotease amina siklik tersubstitusi | |
PT983267E (pt) | Compostos sulfonamida amidoaromaticas de acido hidroxamico | |
EA200101085A1 (ru) | Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз | |
EA200300906A1 (ru) | Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7 | |
RU93036185A (ru) | Ингибиторы с двойным действием | |
EA200201271A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
EA199800943A1 (ru) | Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы | |
DE69819878D1 (de) | Divalente sulfonyl-aryl-oder heteroaryl hydroxamsäureverbindungen | |
EA200100971A1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
EA200100804A1 (ru) | Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз | |
AR012264A1 (es) | Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada | |
CA2264254A1 (en) | Phosphinic acid amides as matrix metalloprotease inhibitors | |
CO4920240A1 (es) | Compuestos inhibidores de metaloproteasa diheterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion | |
EA199900421A1 (ru) | Бензонафтиридины в качестве бронхиальных терапевтических средств | |
TR199900401T2 (xx) | Bidentat metaloproteaz inhibit�rleri. | |
AU2558300A (en) | Substituted stilbene compounds with vascular damaging activity | |
EA200400708A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
EA199900057A1 (ru) | Ингибиторы матриксных металлопротеиназ | |
BR0109328A (pt) | Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica | |
ATE516027T1 (de) | Orazamid orotat zur vorbeugung von leberschäden | |
WO2001070720A3 (en) | Carbocyclic side chain containing, n-substituted metalloprotease inhibitors | |
EA200100297A1 (ru) | Моногидрат гидробромида элетриптана | |
EA200400707A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
EA200001140A1 (ru) | СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC1A | Change in name of an applicant in a eurasian application | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |